As shown by our data, administration of DHZCPs significantly increased the expression levels of ghrelin and adiponectin but decreased the expression level of leptin in NAFLD patients treated with DHZCPs. Here, LEP is linked to metabolic dysfunction-associated steatotic liver disease.